-
JW Therapeutics Secures NMPA Review for CAR-T Therapy in Mantle Cell Lymphoma
•
JW Therapeutics (HKG: 2126), a Chinese biopharmaceutical company, has announced that it has submitted an additional indication application for its chimeric antigen receptor (CAR) T cell therapy, Carteyva (relmacabtagene autoleucel injection), targeting recurrent or refractory mantle cell lymphoma (r/r MCL). The National Medical Products Administration (NMPA) has accepted the filing…
-
China’s Ministry of Education Launches Professional Guidelines for Healthcare Talent Training
•
The Ministry of Education (MoE) in China has issued a Notice outlining the “Professional Guidelines for Training Talent in the Healthcare Industry,” which includes the establishment of five new medical majors for universities to offer to Chinese students. The initiative, crafted by MoE experts, is designed to nurture talents in…
-
Jiangsu Hengrui Medicine Advances Novel Cancer Therapies with NMPA Clinical Trial Approval
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has received approval from the National Medical Products Administration (NMPA) to conduct an open-label, multi-center Phase Ib/II clinical study. The study will assess the efficacy of three of the company’s novel pipeline candidates in combination regimens against general solid tumors. The drugs in…
-
Suzhou Elite Analytical Instruments Secures Over $14 Million in Initial Funding Round
•
Suzhou Elite Analytical Instruments Co., Ltd, a leading specialist in liquid chromatography based in China, has reportedly raised more than RMB 100 million (USD 14 million) in its first-ever financing round. The funding was co-led by Jifeng Ventures and SND Rongsheng Investment, with additional investments from SIDVC, Qiaojing Capital, New…
-
Jiangsu Vcare PharmaTech Submits NDA to US FDA for Vicagrel, a P2Y12 Receptor Antagonist
•
Jiangsu Vcare PharmaTech Co., Ltd, a Chinese pharmaceutical company, has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its vicagrel, a P2Y12 receptor antagonist. The drug is proposed for the treatment of acute coronary syndrome (ACS), ischemic stroke, and thrombotic cardiovascular and diagnosed…
-
Allorion Therapeutics and Avenzo Seal Deal for Global Rights to CDK2 Inhibitor
•
China-based Allorion Therapeutics has entered into a licensing agreement with Avenzo Therapeutics Inc., granting the US firm global development and commercialization rights (excluding Greater China) to Allorion’s cyclin-dependent-kinases 2 (CDK2) inhibitor. The agreement also includes an exclusive option for a pre-clinical program anticipated for IND filing in 2025. As part…
-
BMS’s Sotyktu, First TYK2 Inhibitor, Hits Chinese Market
•
US pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced the market launch of Sotyktu (deucravacitinib) in China, marking a significant milestone for the treatment of moderate to severe plaque psoriasis. Sotyktu is recognized as the world’s first and only TYK2 allosteric inhibitor, suitable for patients eligible for systemic…
-
China’s National People’s Congress Approves Stricter Punishments for Sector-Specific Bribery
•
The 7th meeting of the 14th National People’s Congress Standing Committee has passed the latest Amendment (XII) to China’s Criminal Law, which is set to take effect from March 1, 2024. This revision enhances the potential penalties associated with bribery in sectors including healthcare, food and drug industries, and other…
